Content
08/07/2025
Boston, MA USA
Strand Therapeutics
completed $153 million Series B Round funding. Investors include
Kinnevik (lead), Regeneron Ventures, ICONIQ Growth, Amgen Ventures, Alderline Group, LG Technology Ventures, FPV Ventures, Playground Global, Eli Lilly and Company, ANRI, Potentum Partners.
About
Strand Therapeutics is leading the next generation of programmable mRNA therapies: where synthetic biology meets programmable biology to unlock the full potential of gene regulation and delivery inside the body. Unlike traditional mRNA technologies, Strand’s platform programs RNA to think, enabling logic-controlled expression, precision delivery, and unprecedented control over therapeutic outcomes.
Startup
Sector:
Biotech
Life Science
Download StockFan App
Ad
Stock market data, news and community, all integrated.
Features include real time stock quotes, interactive charts, technical signals, institutional & insider ownerships, stock screener, ETF rankings, SEC filings, press releases, videos, earnings calendar, social media posts, group chats.
